Guangzhou, December 18, 2023: BIO Integration (BIOI) publishes volume 4, issue 4. BIOI is a peer-reviewed, open access, international journal, which is dedicated to spreading multidisciplinary views driving the advancement of modern medicine. Aimed at bridging the gap between the laboratory, clinic, and biotechnology industries, it offers a cross-disciplinary platform devoted to communicating advances in the biomedical research field and offering insights into different areas of life science, to encourage cooperation and exchange among scientists, clinical researchers, and health care providers.

The issue contains three research articles, a brief report, and a voice series interview offering insights into different areas of life science in both China and internationally:

Research Articles

The first original article is entitled Single-Cell RNA-Sequencing Integration Analysis Revealed Immune Cell Heterogeneity in Five Human Autoimmune Diseases.  Based on an integration of the single-cell RNA-seq results, the authors of this article demonstrated changes in the immune cell landscape of five different autoimmune diseases with respect to immune cell subsets, populations, differentially-expressed genes, and the cell-to-cell communication network. This data provides new insight to further explore the heterogeneity and similarity among different autoimmune diseases.

The second article is entitled Diabetes Mellitus and Pancreatic Cancer: Investigation of Causal Pathways Through Mendelian Randomization Analysis. A causal relationship exists between diabetes mellitus and the occurrence of pancreatic cancer. People with diabetes mellitus are at high risk of pancreatic cancer and should receive early screening. The IGF signaling pathway may be a key mediator of the effects of diabetes on pancreatic cancer pathogenesis.

The third article is entitled HER2-targeting Peptide Drug Conjugate with Better Penetrability for Effective Breast Cancer Therapy. The authors of this article have developed a HER2-targeting peptide-mertansine conjugate with specific cellular uptake that resulted in longer retention times in vitro and In vivo. HER2-TPMC (~5 kDa in size) exhibited rapid tissue penetration and enhanced tumoral uptake and retention in vitro and In vivo. Therefore, HER2-TPMC is a reasonable alternative for HER2-positive cancer chemotherapeutics.

Brief Report

Entitled Preliminary Investigation into Ultrasound and MRI Presentation of Large-Cell Neuroendocrine Carcinomas of the Uterine Cervix. Conventional ultrasound, contrast-enhanced ultrasound and MRI are complementary methods that provide additional imaging information for the diagnosis of cervical large-cell neuroendocrine carcinoma.

Voice Series

Voice Series: Interview with Professor Dr. Xin Gao, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences

BIO Integration has adopted a continuous article publication process from 2024 and will move to a new article hosting platform at ScienceOpen.